Drug Discovery Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023 - 2028)

The Drug Discovery Market is Segmented by Drug Type (Small Molecule Drugs and Biologic Drugs), Technology (High Throughput Screening, Pharmacogenomics, Combinatorial Chemistry, Nanotechnology, and Other Technologies), End User (Pharmaceutical Companies, Contract Research Organizations (CROs), and Other End Users), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report offers market forecasts and revenues in terms of value in USD million for the above segments.

Drug Discovery Market Size

Drug Discovery Market Summary
Study Period: 2019-2027
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 8.2 %

Major Players

Drug Discovery Market Major Players

*Disclaimer: Major Players sorted in no particular order

setting-icon

Need a report that reflects how COVID-19 has impacted this market and it's growth?

Drug Discovery Market Analysis

The drug discovery market was valued at USD 58,324.97 million in the base year, and it is expected to reach USD 91,107.71 million by the end of the forecast period, registering a CAGR of 8.2%.

Amid the COVID-19 pandemic, the health systems of various countries rapidly invested in research and development to combat the virus. Potential compounds were screened from the CHEMBL, ZINC, FDA-approved drugs, and molecules under clinical trials. Research groups worldwide have identified drugs for the treatment of COVID-19 by screening both novel and existing drugs for their ability to alleviate symptoms and stop viral replication. Thus, the drug discovery market was positively impacted due to the urge to find a cure for COVID-19. Furthermore, post the pandemic, there is a rise in investments in different modalities of drug development, such as gene and cell therapies for both COVID-19 diseases and other novel diseases, which is expected to impact the market's growth as per the analysis positively. Furthermore, the research for developing antiviral drugs for COVID-19 is still in progress. For instance, in May 2022, the National Institute of Allergy and Infectious Diseases (NIAID) awarded approximately USD 577 million to establish nine Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern. The AViDD centers will carry out creative, interdisciplinary research to create candidate COVID-19 antivirals, particularly those that can be used outside of a hospital setting, as well as antivirals that target particular viral families with a high potential to trigger a pandemic in the future. Such grants are expected to drive the drug discovery market's growth post-pandemic.

The propelling factors for the growth of the drug discovery market include the rising burden of a wide range of diseases (such as cardiovascular and CNS-related disorders), rising healthcare expenditure, and the upcoming patent expiration of blockbuster drugs.

Cardiovascular diseases, infectious diseases, diabetes, and kidney-related complications are highly prevalent worldwide. According to key facts about cardiovascular diseases (CVDs) published by the WHO in June 2021, CVDs are the leading cause of death globally, representing around 32% of all global deaths. CVD remains the leading cause of death and disability and remains highly complicated, costly, and burdensome. Moreover, new strategies are required to streamline and reduce the costs of clinical trials while placing greater importance on the patient experience and voice. Thus, the increasing burden of a diverse range of diseases among all age groups and its burden globally drive the demand for drug discovery and its market.

Furthermore, there has been an upsurge in the usage of advanced technologies, such as high-throughput process development, bioinformatics, and combinatorial chemistry, for better drug candidate identification. Drug discovery has evolved significantly with emerging technologies, helping the process become more refined, accurate, and time-efficient. The adoption of artificial intelligence systems in disease diagnostics and treatment design is growing, and this is expected to witness robust growth in the coming years. For instance, in March 2020, Existencia, an AI-based drug discovery company, entered a collaborative agreement with Diamond Light Source and Scripps Research to identify COVID-19 antiviral therapies. Thus, these factors are anticipated to contribute to the market's growth over the forecast period.

However, the huge capital investment, low-profit margins, and stringent drug discovery regulations are expected to hinder the market growth.

Drug Discovery Industry Segmentation

As per the scope of the report, drug discovery is a process aimed at identifying a compound that is therapeutically useful in treating and curing diseases. Typically, a drug discovery effort addresses a biological target that has been shown to play a role in the development of the disease or starts from a molecule with interesting biological activities. In the recent past, drug discovery has evolved significantly with emerging technologies, helping the process become more refined, accurate, and time-consuming. 

The drug discovery market is segmented by drug type (small molecule drugs and biologic drugs), technology (high throughput screening, pharmacogenomics, combinatorial chemistry, nanotechnology, and other technologies), end user (pharmaceutical companies, contract research organizations (CROs), and other end users), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report offers market forecasts and revenues in terms of value in USD million for the above segments.

Drug Type
Small Molecule Drugs
Biologic Drugs
Technology
High Throughput Screening
Pharmacogenomics
Combinatorial Chemistry
Nanotechnology
Other Technologies
End User
Pharmaceutical Companies
Contract Research Organizations (CROs)
Other End Users
Geography
North America
United States
Canada
Mexico
Europe
United Kingdom
Germany
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Drug Discovery Market Trends

This section covers the major market trends shaping the Drug Discovery Market according to our research experts:

Biologics Drug Segment is Expected to Show a Significant Growth Over the Forecast Period.

During the pandemic, the rising adoption of biologics due to their specific advantages, especially target specificity, bodes well for the market studied. As a result, many major biotech firms are in the middle of a race to investigate the SARS-CoV-2 genome and prepare therapeutics. Furthermore, COVID-19 has significantly impacted the growth of biologics due to the rise in the development of biologics for SARS-CoV-2. For instance, in February 2022, AbCellera launched bebtelovimab (LY-CoV1404), the second antibody developed through AbCellera’s collaboration with Eli Lilly and Company (Lilly), which has received Emergency Use Authorization from the FDA for the treatment of mild to moderate COVID-19.

Biologic drugs offer several benefits, such as highly effective and potent action, fewer side effects, and the potential to cure diseases rather than merely treat the symptoms, significantly increasing the demand for these products.​

The efficacy and safety of biologics have led to their rapid adoption by people, driving the growth of the biologics segment. This has led to an increase in partnerships among drug discovery companies for the development of biologics. For instance, in August 2022, Sanofi and Innovent Biologics entered a strategic collaboration to accelerate the development of oncology medicines and expand their presence in China. In addition, in February 2022, Abzena, Alira Health, and Oncodesign launched DRIVE biologics. These companies are entering a consortium to offer their partners synergy and expertise in biologics drug discovery and development programs. Such partnerships are expected to drive the growth of this segment due to the rise in the development and adoption of biologics for various diseases over the forecast period.

Moreover, the rise in approvals for biologics from international regulatory agencies is further expected to propel the growth of this segment. For instance, in February 2022, the FDA accepted for review the Prior Approval Supplement (PAS) to the Biologics License Application (BLA) for ABRILADA (adalimumab-afzb) as an interchangeable biosimilar to Humira (adalimumab). Such initiatives are expected to drive the growth of the biologics segment.

Therefore, owing to the above-mentioned factors, the biologics segment is expected to experience tremendous growth.

Drug Discovery Market : Estimates of Funding for Gene Therapy (in USD Million), United States, 2017-2021

North America is Expected to Hold a Significant Market Share Over the Forecast Period

North America has a significant share of the world's R&D spending on pharmaceuticals and biologics. The factors contributing to the growth of this region include a rise in investments by drug development companies, huge grants from the government of the United States, a strong foothold of major drug development companies, well-developed healthcare infrastructure, and a rise in chronic diseases, among others.

For instance, according to the ACS "Cancer Facts & Figures 2022," around 1,918,030 new cancer cases and 609,360 deaths due to cancer are estimated to be reported in the United States by the end of 2022. Such a high incidence of cancer in this region is anticipated to drive drug discovery for cancer, driving the market growth.

Furthermore, the rise in technological advancements in drug discovery in the United States is expected to drive the drug discovery market in this region. For instance, in September 2022, CytoReason entered a multi-year partnership with Pfizer to use CytoReason’s artificial intelligence technology for Pfizer’s drug development program. Such collaborations among key market players in the United States to implement AI technology in drug discovery are expected to drive the growth of this market studied in this region.

Therefore, owing to the above-mentioned factors, the drug discovery market is expected to increase over the forecast period.

Drug Discovery Market- Growth Rate by Region

Drug Discovery Industry Overview

The drug discovery market is highly competitive and consists of a number of major players. The market players are implementing innovative strategies and adopting artificial intelligence and machine learning in drug discovery to speed up the process. Furthermore, the key market players are entering into strategic partnerships to develop novel drug molecules. Some of the companies in this market include Eli Lilly and Company, Novartis AG, Bayer AG, AbbVie Inc., AstraZeneca PLC, F. Hoffmann-La Roche Ltd., Pfizer Inc., and Sanofi.

Drug Discovery Market Leaders

  1. Eli Lilly and Company

  2. Bristol-Myers Squibb Company

  3. Novartis AG

  4. Bayer AG

  5. AbbVie Inc.

*Disclaimer: Major Players sorted in no particular order

Drug Discovery Market Concentration

Drug Discovery Market News

  • October 2022: Verge Genomics, a clinical-stage and technology-enabled biotechnology company pioneering the use of artificial intelligence (AI) and human data to transform drug discovery, announced dosing the first subject in its Phase 1 clinical trial of VRG50635.
  • October 2022: NGM Bio released topline results from the CATALINA Phase 2 Trial of NGM621 in patients with geographic atrophy (GA) secondary to age-related macular degeneration.

Drug Discovery Market Report - Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rising Burden of Various Chronic Diseases

      2. 4.2.2 Increasing R&D Expenditure and Investment in the Development of Novel Drug Molecules

    3. 4.3 Market Restraints

      1. 4.3.1 Huge Capital Investment with Low Profit Margins

      2. 4.3.2 Stringent Government Regulations

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION (Market Size by Value - USD Million)

    1. 5.1 Drug Type

      1. 5.1.1 Small Molecule Drugs

      2. 5.1.2 Biologic Drugs

    2. 5.2 Technology

      1. 5.2.1 High Throughput Screening

      2. 5.2.2 Pharmacogenomics

      3. 5.2.3 Combinatorial Chemistry

      4. 5.2.4 Nanotechnology

      5. 5.2.5 Other Technologies

    3. 5.3 End User

      1. 5.3.1 Pharmaceutical Companies

      2. 5.3.2 Contract Research Organizations (CROs)

      3. 5.3.3 Other End Users

    4. 5.4 Geography

      1. 5.4.1 North America

        1. 5.4.1.1 United States

        2. 5.4.1.2 Canada

        3. 5.4.1.3 Mexico

      2. 5.4.2 Europe

        1. 5.4.2.1 United Kingdom

        2. 5.4.2.2 Germany

        3. 5.4.2.3 France

        4. 5.4.2.4 Italy

        5. 5.4.2.5 Spain

        6. 5.4.2.6 Rest of Europe

      3. 5.4.3 Asia-Pacific

        1. 5.4.3.1 China

        2. 5.4.3.2 Japan

        3. 5.4.3.3 India

        4. 5.4.3.4 Australia

        5. 5.4.3.5 South Korea

        6. 5.4.3.6 Rest of Asia-Pacific

      4. 5.4.4 Middle East and Africa

        1. 5.4.4.1 GCC

        2. 5.4.4.2 South Africa

        3. 5.4.4.3 Rest of Middle East and Africa

      5. 5.4.5 South America

        1. 5.4.5.1 Brazil

        2. 5.4.5.2 Argentina

        3. 5.4.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 AbbVie Inc.

      2. 6.1.2 Bristol-Myers Squibb Company

      3. 6.1.3 AstraZeneca PLC

      4. 6.1.4 Bayer AG

      5. 6.1.5 Eli Lilly and Company

      6. 6.1.6 F. Hoffmann-La Roche Ltd

      7. 6.1.7 GlaxoSmithKline PLC

      8. 6.1.8 Merck & Co. Inc.

      9. 6.1.9 Novartis

      10. 6.1.10 Pfizer Inc.

      11. 6.1.11 Takeda Pharmaceuticals

      12. 6.1.12 Sanofi

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape Covers - Business Overview, Financials, Products and Strategies, and Recent Developments
You can also purchase parts of this report. Do you want to check out a section wise price list?

Drug Discovery Market Research FAQs

The Drug Discovery Market market is studied from 2019 - 2027.

The Drug Discovery Market is growing at a CAGR of 8.2% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Eli Lilly and Company, Bristol-Myers Squibb Company, Novartis AG, Bayer AG, AbbVie Inc. are the major companies operating in Drug Discovery Market.

Drug Discovery Industry Report

Statistics for the 2023 Drug Discovery market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Drug Discovery analysis includes a market forecast outlook to 2028 and historical overview. Get a sample of this industry analysis as a free report PDF download.

close-icon
80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!